Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:17 AM
Study NCT ID:
NCT00186277
Status:
COMPLETED
Last Update Posted:
2011-03-30
First Post:
2005-09-13
Brief Title:
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Sponsor:
Stanford University
Organization:
Stanford University
Study Overview
Official Title:
Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer
Status:
COMPLETED
Status Verified Date:
2011-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To combine oxaliplatin and taxotere in patients who have had prior cisplatin therapy in bladder cancer
Detailed Description:
To test the combination of oxaliplatin chemotherapy in combination with taxotere chemotherapy in patients with advanced bladder cancer who have failed one prior chemotherapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| BLDR0001 | OTHER | Stanford University | None |